Ondansetron after ED Visits in Children with Gastroenteritis. Reply
Abstract
To the Editor: The recent trial by Freedman et al. (July 17 issue) 1 provides compelling evidence supporting the role of ondansetron as an “on-demand” antiemetic rather than routine medication for pediatric gastroenteritis. Their trial shows that ondansetron, when dispensed for contingent use after discharge from the emergency department (ED), effectively halves the incidence of moderate-to-severe illness, despite minimal consumption by most children, which emphasizes the importance of precision medicine. 2 However, their findings underscore a critical nuance that is frequently overlooked — the diminishing returns of multiple-dose regimens. Increased incidence of diarrhea among children receiving multiple doses supports the biologic rationale . . .
Read the paper
Related studies
- Patient-Centered Pharmaceutical Design to Improve Acceptability of Medicines: Similarities and Differences in Paediatric and Geriatric Populations
- Evidence-based clinical practice guidelines for irritable bowel syndrome 2020
- Phase 2b Study of Pimodivir (JNJ-63623872) as Monotherapy or in Combination With Oseltamivir for Treatment of Acute Uncomplicated Seasonal Influenza A: TOPAZ Trial
- Gastrointestinal manifestations in COVID-19
- COVID-19 and Gastrointestinal Disease: Implications for the Gastroenterologist
- Persistent gut barrier damage and commensal bacterial influx following eradication of Giardia infection in mice
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.